



Letter
Paper #2

SHEET 1 OF 2

| | | |
|---|---|---|
| U.S. PATENT & TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | ATTY DOCKET NO. ALLIA.228A | APPLICATION NO. 09/919,477 |
| | FILING DATE 30 July 2001 | GROUP Unknown |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) |
|------------------|--|
| <i>Gul</i> | 1. Andya, James D. et al. <i>The Effect of Formulation Excipients on Protein Stability and Aerosol Performance of Spray-Dried Powders of a Recombinant Humanized Anti-IgE Monoclonal Antibody</i> , 16(3) <i>Pharmaceutical Res.</i> , pp 350-358 (1999). |
| | 2. Bustami, Rana T. et al. <i>Generation of Micro-Particles of Proteins for Aerosol Delivery Using High Pressure Modified Carbon Dioxide</i> , 17(11) <i>Pharmaceutical Res.</i> , pp 1360-1366 (2000). |
| | 3. Bosquillon, Cynthia et al. <i>In Uence of Formulation Excipients and Physical Characteristics of Inhalation Dry Powders on their Aerosolization Performance</i> , 70 <i>J. of Controlled Release</i> , pp 329-339 (2001). |
| | 4. Christensen, K. L. et al, <i>Preparation of Redispersible Dry Emulsions by Spray Drying</i> , 212 <i>Int. J. of Pharmaceutics</i> , pp 187-194 (2001). |
| | 5. Costantino, Henry R., et al. <i>Effect of Mannitol Crystallization on the Stability and Aerosol Performance of a Spray-Dried Pharmaceutical Protein, Recombinant Humanized Anti-IgE Monoclonal Antibody</i> , 87(11) <i>J. of Pharmaceutical Sciences</i> , pp 1406-1411 (Nov. 1998). |
| | 6. Haitsma, Jack J., et al. <i>Exogenous Surfactant as a Drug Delivery Agent</i> , 47 <i>Advanced Drug Delivery Reviews</i> , pp 197-207 (2001). |
| <i>✓</i> | 7. Johansen, Pål, et al. <i>Technological Considerations Related to the Up-Scaling of Protein Microencapsulation b Spray-Drying</i> , 50 <i>European J. of Pharmaceutics and Biopharmaceutics</i> , pp 413-417 (2000). |

| | | | |
|----------|------------------|-----------------|--------|
| EXAMINER | David A. Saenger | DATE CONSIDERED | 2/6/04 |
|----------|------------------|-----------------|--------|

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



| | | | | | | | | | |
|---|-------------------------------|-------------------------------|--|--|--|--|--|--|-------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE | ATTY DOCKET NO. ALLIA.228A | APPLICATION NO. 09/919,477 | | | | | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | APPLICANT Bot et al. | | | | | | | | |
| | FILING DATE 30 July 2001 | GROUP Unknown | | | | | | | |
| | | | | | | | | | 164af |

| EXAMINER INITIAL | U.S. PATENT DOCUMENTS | | | | | | | | | CLASS | SUBCLASS | FILING DATE |
|------------------|-----------------------|-----|-----|-----|-----|-----|---|---|------|-------|----------|-------------|
| | D N | O U | C M | U B | M E | E R | N | T | DATE | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |

| EXAMINER INITIAL | FOREIGN PATENT DOCUMENTS | | | | | | | | | CLASS | SUBCLASS | TRANSLATION YES NO |
|------------------|--------------------------|-----|-----|-----|-----|-----|---|---|------|-------|----------|--------------------|
| | D N | O U | C M | U B | M E | E R | N | T | DATE | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | | | | | | | | | | | |
|------------------|--|--|--|--|--|--|--|--|--|--|--|--|
| Deej | 8 Johnson, Keith A., <i>Preparation of Peptide and Protein Powders for Inhalation</i> , 26 Advanced Drug Delivery Reviews, pp 3-15 (1997). / | | | | | | | | | | | |
| | 9 Millqvist-Fureby, Anna, et al. <i>Spray-Drying of Trypsin - Surface Characterisation and Activity Preservation</i> , 188 Int. J. of Pharmaceutics, pp 243-253 (1999). | | | | | | | | | | | |
| | 10 Mitra, Ranjana et al., <i>Enhanced Pulmonary Delivery of Insulin by Lung Lavage Fluid and Phospholipids</i> , 217 Int. J. of Pharmaceutics, pp 25-31 (2001). | | | | | | | | | | | |
| | 11 Moghimi, S. Moein et al., <i>Recognition by Macrophages and Liver Cells of Opsonized Phospholipid Vesicles and Phospholipid Headgroups</i> , 18(1) Pharmaceutical Res., pp 1 - 8 (2001). | | | | | | | | | | | |
| | 12 Patton, John S. et al., <i>Inhaled Insulin</i> , 35 Advanced Drug Delivery Reviews, pp 235-247 (1999). | | | | | | | | | | | |
| | 13 Santinho, Ana J.P., et al., <i>Influence of Formulation on the Physicochemical Properties of Casein Microparticles</i> , 186 Int. J. of Pharmaceutics, pp 191-198 (1999). / | | | | | | | | | | | |
| | 14 Schöler N., et al., <i>Surfactant, But Not The Size Of Solid Lipid Nanoparticles (SLN) Influences Viability And Cytokine Production Of Macrophages</i> , 221 Int. J. of Pharmaceutics pp 57-67 (2001). / | | | | | | | | | | | |
| | 15 Todo, Hiroaki et al., <i>Effect of Additives on Insulin Absorption From Intratracheally Administered Dry Powders in Rats</i> , 220 Int. J. of Pharmaceutics, pp 101-110 (2001). / | | | | | | | | | | | |
| | 16 Trolle, S. et al., <i>In Vivo Fate and Immune Pulmonary Response After Nasal Administration of Microspheres Loaded with Phosphorylcholine-Thyroglobulin</i> 183 Int. J. of Pharmaceutics pp 73-79 (1999). / | | | | | | | | | | | |
| ↓ | 17 Williams III, R.O, et al. <i>Formulation of a Protein with Propellant HFA 134a for Aerosol Delivery</i> , 7 European J. of Pharmaceutical Sciences, pp 137-144 (1998). | | | | | | | | | | | |

| | | | |
|----------|--------------------------|-----------------|---------------|
| EXAMINER | <i>David A. St. Onge</i> | DATE CONSIDERED | <i>2/6/04</i> |
|----------|--------------------------|-----------------|---------------|

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*attach
paper* 46
SHEET 1 OF 1

| | | | |
|--|--|--------------------------------|-------------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. ALLIA.228A | APPLICATION NO. 09/919,477 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | APPLICANT Bot, et al. | |
| (USE SEVERAL SHEETS IF NECESSARY) | | FILING DATE July 30, 2001 | GROUP Unknown 1644 |

*PATENT & TRADEMARK
OFFICE*

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|------------------|--|-----------------|------|------|-------|----------|---------------------------------|
| | | | | | | | |
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
|------------------|--|-----------------|------|---------|-------|----------|-------------|
| | | | | | | | YES NO |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | |
|------------------|--|--|
| <i>bday</i> | 1. Avrameas, et al., <i>Eur. J. Immunol.</i> , 26:394-400, 1996 | |
| | 2. Bach, J.F., <i>Endocr. Rev.</i> , 1994 | |
| | 3. Baekkeskov, et al., <i>Autoimmunity</i> , 15 Supp. 24-26, 1993 | |
| | 4. Dahl, et al., <i>Infection and Immunity</i> , 64:399-405, 1996 | |
| | 5. Daniel, et al., <i>Eur. J. Immunol.</i> , 25:1056-1062, 1995 | |
| | 6. Gerner, et al., <i>J. Leukoc. Biol.</i> , 55:161-168, 1994 | |
| | 7. Gower's Handbook of Industrial Surfactants 1993, Pages 885-904 | |
| | 8. Keller, et al., <i>Lancet</i> , 341:927-928, 1993 | |
| | 9. Kimpimaki, et al., <i>J. Clin. Endocrinol. Metab.</i> , 85:1126-1132, 2000 | |
| | 10. MERCK index 11 ed., pg. 313, 1989 | |
| | 11. Pacheco-Soares, et al., <i>Braz. J. Med. Biol. Res.</i> , 25:1015-1024, 1992 | |
| | 12. Prigozy, et al., <i>Immunity</i> , 6:187-197, 1997 | |
| | 13. Reise Sousa, et al., <i>J. Exp. Med.</i> , 178:509-517, 1993 | |
| | 14. Roll, et al., <i>Diabetes</i> , 45:967-943, 1996 | |
| | 15. Schlesinger, L. S., <i>J. Immunol.</i> , 150:2920-2930, 1993 | |
| | 16. Simoné, et al., <i>Diabetes Care</i> , 22 Supp. 2:B7-B15, 1999 | |
| | 17. Stahl, P.D., <i>Curr. Opin. Immunol.</i> , 4:49-72, 1992 | |
| | 18. Wilson and Pearson, <i>J. Immunol.</i> , 136:4681-4688, 1986 | |
| | 19. Yamamoto, et al., <i>Infect. Immun.</i> , 65:1077-1082, 1997 | |

COPY OF PAPERS
ORIGINALLY FILED

S:\DOCS\JOM\JOM-2389.DOC

| | |
|--|-------------------------------|
| EXAMINER <i>Daniel A. Scarsella</i> | DATE CONSIDERED <i>2/6/04</i> |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
TECHNIKER
AUG 3 2004
160-26900

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 09/919,477 |
| Filing Date | 07/30/2001 |
| First Named Inventor | Adrian Bot et al. |
| Group Art Unit | 1614 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 0157.00 |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| AI | AI | NEWMAN, "Ovalbumin peptide encapsulated in poly(d,L lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response," J. Cont. Rel., p. 49-59, | |
| AJ | AJ | AMSELEM, "Polymeric Biodegradable Liposomes as Vaccine Delivery Systems," Poly. for Adv. Tech., p. 351-357, | |
| AK | AK | ALONSO, "Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres," Pharm. Res., p. 945-953, | |
| AL | AL | EVORA, "Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine," J. of Cont. Rel., p. 143-152, | |
| AM | AM | EDWARDS, "Large Porous Particles for Pulmonary Drug Delivery," Science, p. 1868-1871, | |
| AN | AN | RUEDL, "Enhancement of the Local Immune Response in the Respiratory System by Bacterial Immunomodulators," Regional Immu., p. 361-364, | |
| AO | AO | JEFFERY, "The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique," Pharm. Res., p. 362-368, | |
| AP | AP | ARTURSSON, "Biodegradable microspheres V: Stimulation of macrophages with microparticles made of various polysaccharides," J. of Pharm Sciences, p. 127-133, | |
| AQ | AQ | ARTURSSON, "Characterization of polyacryl starch microparticles as carriers for proteins and drugs," J. of Pharm. Sciences, p. 1507-1513, | |
| AR | AR | COX, "Adjuvants - a classification and review of their modes of action," Vaccine, p. 248-256, | |
| AS | AS | BOT, "Receptor-Mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine," Pharm. Res. , p. 971-979, | |

Examiner
Signature

David A. Saunders

Date
Considered

2/5/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

| | |
|-------------------|-----------------|
| ATTY. DOCKET NO. | APPLICATION NO. |
| 17945.014 | 09/919,477 |
| APPLICANTS | |
| Adrian BOT et al. | |
| FILING DATE | GROUP |
| July 30, 2001 | 1614 1644 |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE |
|------------------|-----------------|-----------|---------|----------------|-----------|-------------|
| DWJ | AA1 | 5,985,309 | 11/1999 | Edwards et al. | / | / |
| | AB1 | | | | | |
| | AC1 | | | | | |
| | AD1 | | | | | |
| | AE1 | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|------------------|-----------------|----------|---------|-------|-----------|-------------|
| DWJ | AF1 | 88/01862 | 3/1988 | PCT | / | Yes No |
| | AG1 | | | | | Yes No |
| | AH1 | | | | | Yes No |
| | AI1 | | | | | Yes No |
| | AJ1 | | | | | Yes No |

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

| | | | |
|-----|----|---|---|
| DWJ | AK | 1 | International Search Report, PCT/US02/13145, issued August 20, 2002 |
| | AL | 1 | |
| | AM | 1 | |
| | AN | 1 | |
| | AO | 1 | |
| | AP | 1 | |

EXAMINER Dwight A Saunders DATE CONSIDERED 2/6/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
TECH CENTER 1600/2900
NOV 18 2002